{"id":6692,"date":"2019-10-22T12:33:46","date_gmt":"2019-10-22T10:33:46","guid":{"rendered":"https:\/\/www.endoscopy-campus.com\/?post_type=ec-news&p=6692"},"modified":"2019-10-22T12:44:50","modified_gmt":"2019-10-22T10:44:50","slug":"ustekinumab-is-efficacious-for-induction-and-maintenance-of-uc","status":"publish","type":"ec-news","link":"https:\/\/www.endoscopy-campus.com\/en\/ec-news\/ustekinumab-is-efficacious-for-induction-and-maintenance-of-uc\/","title":{"rendered":"Ustekinumab Is Efficacious for Induction and Maintenance of UC"},"content":{"rendered":"\n

Monika Fischer, MD, FASGE reviewing Sands BE, et al. N Engl J Med 2019 Sep 26.<\/em><\/strong><\/p>\n\n\n\n

Ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, is currently available in the U.S. for induction and maintenance of remission in moderate to severe Crohn\u2019s disease. <\/p>\n\n\n\n

In phase 3 of the UNIFI trial, 961 patients with ulcerative colitis (UC) were randomized to either a 130 mg or 6 mg\/kg intravenous induction dose of ustekinumab. Only patients who responded to induction at 8 weeks were further randomized to subcutaneous maintenance injections of 90 mg either every 8 weeks or every 12 weeks. At week 8, the proportion of patients in clinical remission was the same in the 130-mg group (15.6%) and the 6-mg\/kg group (15.5%) and was significantly higher compared to that in the placebo group (5.3%, P<0.001). At 44 weeks, the proportion of patients in clinical remission on the dosing every 12 weeks (38.4%) or 8 weeks (43.8%) was higher than the clinical remission rate among those assigned to a placebo (24.0%) (P=0.002 and P<0.001, respectively). Antibodies were detected in only 4.5% of patients. It is noteworthy that 7 out of 825 patients on ustekinumab were diagnosed with various types of cancer. Ustekinumab was more efficacious than a placebo in inducing and maintaining clinical remission (at 8 and 44 weeks) in moderate to severe active UC.<\/p>\n\n\n\n

<\/div>\n\n\n\n

COMMENT
Ustekinumab will soon enrich our armamentarium of injectable medications for UC. Time will tell where to position ustekinumab in the treatment paradigm. <\/p><\/blockquote><\/figure>\n\n\n\n

<\/div>\n\n\n\n
\"\"<\/figure>
\n

Monika Fischer, MD, FASGE <\/p>\n<\/div><\/div>\n\n\n\n

<\/div>\n\n\n\n

CITATION(S) <\/h2>\n\n\n\n

Sands BE, Sandborn WJ, Panaccione R, et al; UNIFI Study Group. Ustekinumab as induction and maintenance therapy for ulcerative colitis. N Engl J Med<\/em>. 2019;381:1201-1214. (https:\/\/doi.org\/10.1056\/NEJMoa1900750<\/a>) <\/p>\n","protected":false},"excerpt":{"rendered":"

Monika Fischer, MD, FASGE reviewing Sands BE, et al. N Engl J Med 2019 Sep 26. Ustekinumab, an antagonist of the p40 subunit of interleukin-12 and interleukin-23, is currently available in the U.S. for induction and maintenance of remission in moderate to severe Crohn\u2019s disease.  In phase 3 of the UNIFI trial, 961 patients with … Read more<\/a><\/p>\n","protected":false},"template":"","categories":[1768,1790],"tags":[],"class_list":["post-6692","ec-news","type-ec-news","status-publish","hentry","category-asge-journal-scan","category-ibd"],"_links":{"self":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news\/6692","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/ec-news"}],"about":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/types\/ec-news"}],"wp:attachment":[{"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/media?parent=6692"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/categories?post=6692"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.endoscopy-campus.com\/en\/wp-json\/wp\/v2\/tags?post=6692"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}